Polaris Venture Management Co. V L.L.C. increased its holdings in shares of Selecta Biosciences Inc (NASDAQ:SELB) by 72.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,773,479 shares of the company’s stock after purchasing an additional 1,166,666 shares during the quarter. Selecta Biosciences makes up 5.6% of Polaris Venture Management Co. V L.L.C.’s portfolio, making the stock its 5th biggest holding. Polaris Venture Management Co. V L.L.C. owned approximately 6.19% of Selecta Biosciences worth $6,573,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Wasatch Advisors Inc. grew its holdings in Selecta Biosciences by 2,546.1% during the 1st quarter. Wasatch Advisors Inc. now owns 2,923,702 shares of the company’s stock valued at $6,929,000 after buying an additional 2,813,212 shares in the last quarter. Artal Group S.A. grew its holdings in Selecta Biosciences by 6.8% during the 4th quarter. Artal Group S.A. now owns 600,000 shares of the company’s stock valued at $1,596,000 after buying an additional 38,460 shares in the last quarter. Fosun International Ltd grew its holdings in Selecta Biosciences by 153.4% during the 1st quarter. Fosun International Ltd now owns 438,330 shares of the company’s stock valued at $938,000 after buying an additional 265,330 shares in the last quarter. FMR LLC grew its holdings in Selecta Biosciences by 23.5% during the 4th quarter. FMR LLC now owns 345,046 shares of the company’s stock valued at $918,000 after buying an additional 65,623 shares in the last quarter. Finally, Two Sigma Investments LP grew its holdings in Selecta Biosciences by 87.8% during the 4th quarter. Two Sigma Investments LP now owns 200,498 shares of the company’s stock valued at $533,000 after buying an additional 93,719 shares in the last quarter. Institutional investors and hedge funds own 47.07% of the company’s stock.
SELB has been the subject of several research analyst reports. Mizuho restated a “buy” rating and set a $4.00 price target on shares of Selecta Biosciences in a report on Friday, May 10th. Canaccord Genuity dropped their target price on Selecta Biosciences from $25.00 to $13.00 and set a “buy” rating for the company in a report on Monday, March 18th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $7.00 target price on shares of Selecta Biosciences in a report on Friday, March 15th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the stock. Selecta Biosciences presently has a consensus rating of “Hold” and a consensus target price of $8.04.
Shares of Selecta Biosciences stock opened at $1.88 on Friday. The stock has a market cap of $84.87 million, a PE ratio of -0.64 and a beta of 1.40. The business has a 50 day moving average of $2.18. Selecta Biosciences Inc has a one year low of $1.41 and a one year high of $16.55.
Selecta Biosciences (NASDAQ:SELB) last announced its earnings results on Thursday, May 9th. The company reported ($0.31) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.06. The company had revenue of $0.01 million during the quarter. As a group, equities analysts anticipate that Selecta Biosciences Inc will post -1.35 earnings per share for the current fiscal year.
Selecta Biosciences Profile
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses.
Featured Article: What are the qualifications of a portfolio manager?
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.